Back to Browse Journals » Research Reports in Clinical Cardiology » Volume 2

Critical evaluation of ivabradine for the management of chronic stable angina

Authors Khan W, Borer JS

Published Date September 2011 Volume 2011:2 Pages 87—98

DOI http://dx.doi.org/10.2147/RRCC.S15570

Published 5 September 2011

Waqas Khan, Jeffrey S Borer
Division of Cardiovascular Medicine and the Department of Medicine, State University of New York Downstate Medical Center and College of Medicine, Brooklyn and New York, NY, USA

Abstract: Angina pectoris is the most common symptom of coronary artery disease (CAD). Angina results from an imbalance between myocardial oxygen supply and demand. Heart rate (HR) reduction can beneficially alter both elements of this imbalance by increasing diastolic filling time and reducing myocardial oxygen demand. Therefore, HR reduction is an accepted approach to angina prevention. ß-blockers, calcium-channel blockers, and long-acting nitrates are currently the cornerstones in prevention and management of stable angina. However, use of these treatments may be limited by adverse effects or development of tolerance. Thus, additional approaches to angina prevention may be useful for many patients with CAD. The discovery of the f-channel and the resulting current, If, that modulates the rate of spontaneous diastolic depolarization of sinoatrial nodal (SAN) myocytes led to the study of these channels as targets for lowering HR. This resulted in the development of a novel agent, ivabradine, a selective and specific If inhibitor. Ivabradine slows the slope of diastolic depolarization of the action potential in the SAN cells, decreasing HR at rest and during exercise, but has no other cardiovascular effects. In different subpopulations with chronic stable angina, ivabradine markedly improves exercise capacity and significantly decreases the number of ambient angina attacks. In a post-hoc analysis of the BEAUTIFUL trial (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left-ventricULar dysfunction), ivabradine also reduced mortality, myocardial infarctions, and heart failure hospitalizations among patients with angina. To date, the drug has been well tolerated; transient visual disturbances and bradycardia are the only potentially important, though relatively infrequent, concerns and are readily reversible with drug cessation. This article will review and critically evaluate the data supporting use of ivabradine in patients with CAD and angina, both in preventing the symptom and, potentially, in altering the natural history of CAD.

Keywords: coronary artery disease, cardiovascular pharmacology, clinical trials

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Giant U waves: an important clinical clue

Verma N, Figueredo VM, Greenspan AM, Pressman GS

Research Reports in Clinical Cardiology 2011, 2:51-55

Published Date: 11 April 2011

Cardiovascular disease among patients attending a specialist diabetes clinic in Jamaica

Ferguson TS, Tulloch-Reid MK, Younger NO, Wright-Pascoe RA, Boyne MS, McFarlane SR, Francis DK, Wilks RJ

Research Reports in Clinical Cardiology 2011, 2:41-50

Published Date: 31 March 2011

False elevation of cardiac markers: importance of recognition

Yaser Elnahar, Joseph Daoko, Karim El Kersh, et al

Research Reports in Clinical Cardiology 2011, 2:37-40

Published Date: 23 March 2011

The western diet and lifestyle and diseases of civilization

Pedro Carrera-Bastos, Maelan Fontes-Villalba, James H O’Keefe, et al

Research Reports in Clinical Cardiology 2011, 2:15-35

Published Date: 9 March 2011